I
InCarda Therapeutics
A clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route
About InCarda Therapeutics
InCarda Therapeutics is a biopharmaceutical company focused on developing innovative inhalation therapies for patients experiencing acute episodes of atrial fibrillation (AFib). The company operates in the healthcare and biotechnology market, targeting patients who suffer from this common cardiac arrhythmia. InCarda's primary product is designed to provide rapid relief from AFib symptoms through a novel inhalation delivery system, which offers a non-invasive and efficient alternative to traditional treatments. The business model is centered around the development, clinical testing, and eventual commercialization of its proprietary therapies. Revenue generation will primarily come from the sale of these therapies to healthcare providers and institutions. InCarda is currently in the clinical trial phase, with a focus on demonstrating the efficacy and safety of its products to secure regulatory approval. The company serves a niche market of AFib patients, aiming to address a significant unmet medical need. Key stakeholders include patients, healthcare providers, investors, and regulatory bodies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- West Jordan, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 66.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Pulmonary, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Oct 2020 | $30M | $210M | HealthCap · Morningside · Deerfield · Innoviva | — |
| SERIES BOther financing | Nov 2018 | $42M | $168M | Sofinnova Partners · HealthCap | — |
Growth signals
Latest recorded traffic for InCarda Therapeutics is 430 monthly website visits, up 2.4% over the last three months. InCarda Therapeutics's team declined 8.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Morningside Private Investors
Morningside
HealthCap
Sofinnova Partners
Series B and later3 investors entered at this stage
Asset Management Ventures
Innoviva
Deerfield
Other known investors3 additional known investors
Sofinnova Investments
University of California, Berkeley
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about InCarda Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See InCarda Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.